Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field

Patent metadata

Field	Value
Publication number	US-10016381-B2
Application number	US-201615377013-A
Country	US
Kind code	B2
Filing date	Dec 13, 2016
Priority date	Jul 22, 2005
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

First claim

The invention claimed is:

1. A method of treating ulcerative rectocolitis in a mammal in need thereof, the method comprising administering to the mammal a compound represented by:

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The method of claim 1 , wherein the mammal is a human.

3. The method of claim 1 , wherein the compound is (R)-2-methoxy-3-(4′-aminophenyl)propionic acid.

4. The method of claim 1 , wherein the compound is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid.

5. The method of claim 1 , wherein the compound is in an enantiomerically pure R form.

6. The method of claim 1 , wherein the compound is in an enantiomerically pure S form.

7. A method of treating ulcerative rectocolitis in a mammal in need thereof, the method comprising administering to the mammal a pharmaceutical composition comprising:
a compound represented by:

or a pharmaceutically acceptable salt or a stereoisomer thereof; and
a pharmaceutically acceptable excipient.

8. The method of claim 7 , wherein the mammal is a human.

9. The method of claim 7 , wherein the compound is (R)-2-methoxy-3-(4′-aminophenyl)propionic acid.

10. The method of claim 7 , wherein the compound is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid.

11. The method of claim 7 , wherein the compound is in an enantiomerically pure R form.

12. The method of claim 7 , wherein the compound is in an enantiomerically pure S form.

Assignees

• Nogra Pharma Ltd

Inventors

• Naccari Giancarlo
• Baroni Sergio

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title